27 November 2025
27 November 2025
The second round of IRA negotiations brings the total number of negotiated drugs to 25.
Delivering a budget that was inadvertently leaked early, the UK’s Labour government is continuing its commitment to reshaping healthcare.
The Swiss pharma’s Stein site will discontinue solid dose manufacturing in favour of sterile dose production.
The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.
This licensing deal falls under the biotech’s wider ploy to harness the promise of radiopharmaceuticals within the oncology segment.
The application is based on data from a global, open-label, multicentre Phase I/II study.
Singapore, the Philippines, and Thailand are the pioneers in promoting rare disease awareness among ASEAN.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
